Valbiotis SA (EPA:ALVAL)

Market Cap	22.25M +62.8%
Revenue (ttm)	1.34M +182.1%
Net Income	-8.19M
EPS	-0.34
Shares Out	35.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,771
Open	0.6100
Previous Close	0.6150
Day's Range	0.6100 - 0.6270
52-Week Range	0.4860 - 1.2960
Beta	-0.18
Analysts	Strong Buy
Price Target	1.35 (+115.31%)
Est. Earnings	Dec 29, 2026

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Addition...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2014
• Employees: 50
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVAL

Financial Performance

In 2025, Valbiotis's revenue was 905,000, an increase of 414.20% compared to the previous year's 176,000. Losses were -9.42 million, -6.06% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for ALVAL stock is "Strong Buy." The 12-month stock price target is €1.35, which is an increase of 115.31% from the latest price.

Price Target

€1.35

(115.31% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 12, 2026

Data Sources Report a data error